Important Disclaimer
This article is for educational and informational purposes only. Retatrutide is an investigational medication and is not approved for use in the UK or anywhere else as of July 2026. It is not a medicine and should not be used to treat any medical condition. Always consult a qualified healthcare professional before considering any peptide or weight management option. This content does not constitute medical advice.
What is Retatrutide?
Retatrutide is an investigational once-weekly injectable peptide developed by Eli Lilly. It belongs to a new class of medicines called triple agonists. Unlike semaglutide (which targets one hormone receptor) or tirzepatide (which targets two), retatrutide activates three receptors:
- GLP-1
- GIP
- Glucagon
This triple action is designed to reduce appetite, slow digestion, and increase energy expenditure at the same time.
Latest Clinical Trial Results (2026 Update)
In 2025 and 2026, Eli Lilly released results from the large Phase 3 TRIUMPH trials. Here are the key findings so far:
- In the TRIUMPH-1 trial, participants taking the highest dose (12 mg) lost an average of 28.3% of their body weight over 80 weeks.
- A significant number of people achieved 30% or more weight loss — levels usually seen only with bariatric surgery.
- The medication also showed positive effects on blood sugar control and certain heart health markers.
- Some participants continued to lose weight even after 80 weeks in extension studies.
These results are among the highest seen in any weight management medication currently being studied.
How Does Retatrutide Compare with Semaglutide and Tirzepatide?
| Medication | Type | Average Weight Loss | Status in UK (2026) | Key Difference |
|---|---|---|---|---|
| Semaglutide | GLP-1 | ~15-17% | Approved | Single hormone target |
| Tirzepatide | GLP-1 + GIP | ~20-26% | Approved | Dual hormone target |
| Retatrutide | GLP-1 + GIP + Glucagon | Up to 28.3% | Not approved | Triple hormone target |
Retatrutide is still in the research phase, while semaglutide and tirzepatide are already available as approved treatments in the UK.
Current Availability in the UK (July 2026)
As of now, retatrutide is not approved by the MHRA and is not available through normal prescriptions in the UK. It remains an investigational treatment. Some people discuss it in research or clinical trial contexts, but it is not legally available for general use.
Anyone considering peptides for research purposes should only source them from reputable suppliers who clearly state the products are for laboratory research only. You can explore research peptide options on PeptidesX.uk.
Typical Dosage Information from Trials
In clinical studies, retatrutide was started at a low dose and gradually increased. Common doses studied include 4 mg, 8 mg, and 12 mg once per week. Dosing must always be determined by medical professionals in proper trial settings. Self-administration or sourcing from unregulated channels carries significant risks.
Safety and Side Effects
Like other GLP-1 based medications, retatrutide can cause side effects such as:
- Nausea
- Vomiting
- Diarrhoea
- Decreased appetite
- Injection site reactions
Because it also affects the glucagon receptor, some people experienced additional effects on heart rate and energy levels. Long-term safety data is still being collected.
Strong Warning: Do not use any investigational peptide without proper medical supervision. The long-term effects of retatrutide are still being studied.
Who Might Be Interested in Learning About Retatrutide?
This medication is currently being studied for people with:
- Obesity
- Type 2 diabetes
- Certain heart conditions
It is not suitable for everyone. Only qualified healthcare providers can determine if someone meets the criteria for clinical trials or future approved use.
Frequently Asked Questions
Is retatrutide available in the UK right now? No. It is still under investigation and has not received regulatory approval.
How does retatrutide work differently from other weight loss injections? It targets three hormone pathways instead of one or two, which may explain the higher weight loss seen in trials.
Can I buy retatrutide for research use? Some research peptide suppliers offer compounds for laboratory study only. These are not for human consumption and must be used strictly according to research guidelines.
What happens after the trials finish? If results remain positive, the manufacturer may apply for approval. This process can take additional time.
Final Thoughts
Retatrutide represents an exciting development in weight management research. While the early trial results are promising, it is still an investigational treatment. Anyone exploring options in this area should focus on approved treatments first and always work with qualified medical professionals.
For those conducting legitimate laboratory research, high-quality research compounds are available from specialist suppliers.
For research peptide products and information, visit PeptidesX.uk.